The Wistar Institute
Synthetic DNA-encoded Antibodies Against Zika Virus Shown to be Effective in Preclinical Studies
PHILADELPHIA — (Apr. 5, 2019) — A new approach for delivery of DNA-encoded monoclonal antibodies (DMAbs) has been reported by Wistar scientists and their collaborators. This new technology allows direct production of monoclonal antibody-like molec…
In Memory of Harold Davis, an Extraordinary Wistar Supporter
The Wistar community mourns the loss of a dear friend and one of our greatest supporters, who has given of himself generously to help Wistar for more than four decades. Harold (Hal) M. Davis passed away on Wednesday, Feb. 27, 2019. A suc…
Wistar and the Philadelphia Zoo Work Together to Improve Global Health
The Wistar Institute and the Philadelphia Zoo employ different preventative approaches to improve the health of humans and animals around the world. The Zoo uses conservation and education while Wistar uses biomedical research in vaccines and infe…
New Small Molecule Inhibitors Show Potential for Treatment of Epstein-Barr Virus-Associated Cancers
PHILADELPHIA — (March 6, 2019) — Researchers at The Wistar Institute have created a drug candidate for cancers associated with Epstein-Barr Virus (EBV), the virus that causes infectious mononucleosis. In a study published in Science Translational …
The Wistar Institute and Anixa Biosciences Extend Collaborative Research Agreement
Philadelphia and San Jose, Calif. – (Feb. 21, 2019) – The Wistar Institute has extended its collaboration with Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer. The project i…
New Insight Into the Balance Between the Tumor-suppressive and Tumor-promoting Effects of Cellular Senescence
PHILADELPHIA — (Feb. 18, 2019) — Researchers at The Wistar Institute have described a novel role of nicotinamide adenine dinucleotide (NAD+) metabolism in the ability of senescent cells to release tumor-promoting molecules. This study, published o…
You Are What You Eat: Linking Nutrition, Metabolism and Cancer
As the obesity epidemic climbs, and the connection between nutrition and its effects on health risks and outcomes are top of mind, Wistar’s most recent Women & Science Program featured a comprehensive talk on how what we eat is used by our cel…
Wistar’s David B. Weiner, Ph.D., Awarded Prestigious Scientific Achievement Award from Life Sciences Pennsylvania
PHILADELPHIA — (Feb. 15, 2019) — David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center, and the W.W. Smith Charitable Trust Professor in Cancer Research at The Wistar Institute, has been named the rec…
Wistar Science Highlights: New Synthetic DNA Vaccine for an Emerging Infectious Disease, Combination Treatment for Therapy-resistant Melanoma Patients and New Link Between Cellular Senescence and Cancer
A novel, synthetic DNA vaccine developed by the lab of Kar Muthumani, Ph.D., director of the Laboratory of Emerging Infectious Diseases and assistant professor in Wistar’s Vaccine & Immunotherapy Center at Wistar, induces protective immunity a…
State Funding Awarded to Wistar in Support of its Biomedical Research Training & Workforce Development Programs
PHILADELPHIA — (Feb. 14, 2019) — The Wistar Institute was awarded two grants totaling more than $128,000 from the Pennsylvania Department of Labor & Industry to support the Institute’s training and workforce development initiatives in biomedic…